Cancer clinical trials in the region Île-de-France
787 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 2 Cohorte 1
Required histologic types
Hodgkin lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Breast cancer
Lung cancer
Colon cancer
Rectal cancer
Head and neck cancer
#NCT06657222
Required histologic types
SCLC (Small Cell Lung Cancer)
NSCLC (Non-Small Cell Lung Cancer)
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Tubulis GmbH
Phase 1 / Phase 2
Lung cancer
#NCT06362252
#2023-509629-36-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
8 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2
Lung cancer
#NCT07227298
#2025-523526-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
MET
NTRK-1/2/3
ROS-1
4 recruiting sites
Pfizer
Phase 1 / Phase 2
Kidney cancer
#NCT05287945
Partie B
Required histologic types
Clear cell carcinoma
Papillary carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Oncorena AB
Phase 1 / Phase 2
Lung cancer
#NCT06567015
#2023-510203-21-00
Partie 2 (Optimisation de la dose)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lung cancer
#NCT06567015
#2023-510203-21-00
Partie 1 (Escalade de dose et Backfilling)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lung cancer
#NCT05751798
#2024-514826-22-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
OSE Immunotherapeutics
Phase 1 / Phase 2
Head and neck cancer
#NCT06016920
#2022-503055-26-00
Required histologic types
Oropharynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required HPV statuses
HPV Positive
Required CPS scores
CPS Positive (1 <= X < 20)
CPS Positive (X >= 20)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Car-T
Bispecific T-cell engager antibodies
2 recruiting sites
Nykode Therapeutics ASA
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Acute leukemia
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
Thyroid and adrenal gland cancer
Skin cancer
#NCT07213830
#2025-522184-15-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Ipsen